Skip to Main Content

Although details of the new trade deal between the U.S. and Mexico have not yet been released, a fight is already brewing among some drug makers and consumer advocates over one provision.

At issue is a sentence in a fact sheet that was released this week by the U.S. Trade Representative. A section concerning intellectual property noted there will be 10 years of data protection for biologic drugs and an “expanded scope” of products that will be eligible for protection, although the meaning of this last phrase was not fleshed out.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.